nodes	percent_of_prediction	percent_of_DWPC	metapath
Rifaximin—CYP3A4—Cytarabine—lymphatic system cancer	0.134	0.318	CbGbCtD
Rifaximin—CYP3A4—Teniposide—lymphatic system cancer	0.132	0.313	CbGbCtD
Rifaximin—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0925	0.219	CbGbCtD
Rifaximin—CYP3A4—Vincristine—lymphatic system cancer	0.0636	0.151	CbGbCtD
Rifaximin—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00206	0.00356	CcSEcCtD
Rifaximin—Weight decreased—Vincristine—lymphatic system cancer	0.00206	0.00356	CcSEcCtD
Rifaximin—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.00204	0.00354	CcSEcCtD
Rifaximin—Pneumonia—Vincristine—lymphatic system cancer	0.00204	0.00353	CcSEcCtD
Rifaximin—Flushing—Bleomycin—lymphatic system cancer	0.00203	0.00351	CcSEcCtD
Rifaximin—Depression—Vincristine—lymphatic system cancer	0.00202	0.0035	CcSEcCtD
Rifaximin—Anorexia—Fludarabine—lymphatic system cancer	0.00202	0.00349	CcSEcCtD
Rifaximin—Weight increased—Mitoxantrone—lymphatic system cancer	0.00201	0.00349	CcSEcCtD
Rifaximin—Weight decreased—Mitoxantrone—lymphatic system cancer	0.002	0.00347	CcSEcCtD
Rifaximin—Proteinuria—Methotrexate—lymphatic system cancer	0.002	0.00346	CcSEcCtD
Rifaximin—Hyperglycaemia—Mitoxantrone—lymphatic system cancer	0.002	0.00346	CcSEcCtD
Rifaximin—Pneumonia—Mitoxantrone—lymphatic system cancer	0.00198	0.00344	CcSEcCtD
Rifaximin—Feeling abnormal—Teniposide—lymphatic system cancer	0.00198	0.00343	CcSEcCtD
Rifaximin—Protein urine present—Methotrexate—lymphatic system cancer	0.00197	0.00342	CcSEcCtD
Rifaximin—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00197	0.00341	CcSEcCtD
Rifaximin—Bone disorder—Methotrexate—lymphatic system cancer	0.00195	0.00337	CcSEcCtD
Rifaximin—Nausea—Mechlorethamine—lymphatic system cancer	0.00194	0.00336	CcSEcCtD
Rifaximin—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.00193	0.00334	CcSEcCtD
Rifaximin—Haemoglobin—Carmustine—lymphatic system cancer	0.00192	0.00332	CcSEcCtD
Rifaximin—Urticaria—Teniposide—lymphatic system cancer	0.00191	0.00331	CcSEcCtD
Rifaximin—Haemorrhage—Carmustine—lymphatic system cancer	0.00191	0.0033	CcSEcCtD
Rifaximin—Body temperature increased—Teniposide—lymphatic system cancer	0.0019	0.00329	CcSEcCtD
Rifaximin—Abdominal pain—Teniposide—lymphatic system cancer	0.0019	0.00329	CcSEcCtD
Rifaximin—Hypoaesthesia—Carmustine—lymphatic system cancer	0.0019	0.00328	CcSEcCtD
Rifaximin—Dyspnoea—Fludarabine—lymphatic system cancer	0.00189	0.00327	CcSEcCtD
Rifaximin—Haematuria—Mitoxantrone—lymphatic system cancer	0.00188	0.00326	CcSEcCtD
Rifaximin—Oedema peripheral—Carmustine—lymphatic system cancer	0.00188	0.00325	CcSEcCtD
Rifaximin—Decreased appetite—Fludarabine—lymphatic system cancer	0.00184	0.00318	CcSEcCtD
Rifaximin—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00183	0.00316	CcSEcCtD
Rifaximin—Fatigue—Fludarabine—lymphatic system cancer	0.00182	0.00316	CcSEcCtD
Rifaximin—Hypoaesthesia—Vincristine—lymphatic system cancer	0.00181	0.00313	CcSEcCtD
Rifaximin—Pain—Fludarabine—lymphatic system cancer	0.00181	0.00313	CcSEcCtD
Rifaximin—Constipation—Fludarabine—lymphatic system cancer	0.00181	0.00313	CcSEcCtD
Rifaximin—Urinary tract disorder—Vincristine—lymphatic system cancer	0.0018	0.00311	CcSEcCtD
Rifaximin—Urethral disorder—Vincristine—lymphatic system cancer	0.00178	0.00309	CcSEcCtD
Rifaximin—Haemoglobin—Mitoxantrone—lymphatic system cancer	0.00178	0.00308	CcSEcCtD
Rifaximin—Rhinitis—Mitoxantrone—lymphatic system cancer	0.00178	0.00308	CcSEcCtD
Rifaximin—Hypersensitivity—Teniposide—lymphatic system cancer	0.00177	0.00307	CcSEcCtD
Rifaximin—Haemorrhage—Mitoxantrone—lymphatic system cancer	0.00177	0.00307	CcSEcCtD
Rifaximin—Flushing—Carmustine—lymphatic system cancer	0.00177	0.00306	CcSEcCtD
Rifaximin—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.00176	0.00305	CcSEcCtD
Rifaximin—Pharyngitis—Mitoxantrone—lymphatic system cancer	0.00176	0.00304	CcSEcCtD
Rifaximin—Anaemia—Bleomycin—lymphatic system cancer	0.00176	0.00304	CcSEcCtD
Rifaximin—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00174	0.00302	CcSEcCtD
Rifaximin—Asthenia—Teniposide—lymphatic system cancer	0.00173	0.00299	CcSEcCtD
Rifaximin—Malaise—Bleomycin—lymphatic system cancer	0.00171	0.00297	CcSEcCtD
Rifaximin—Pruritus—Teniposide—lymphatic system cancer	0.0017	0.00295	CcSEcCtD
Rifaximin—Body temperature increased—Fludarabine—lymphatic system cancer	0.00167	0.0029	CcSEcCtD
Rifaximin—Mental disorder—Carmustine—lymphatic system cancer	0.00167	0.00289	CcSEcCtD
Rifaximin—Malnutrition—Carmustine—lymphatic system cancer	0.00166	0.00287	CcSEcCtD
Rifaximin—Cough—Bleomycin—lymphatic system cancer	0.00166	0.00287	CcSEcCtD
Rifaximin—Angiopathy—Vincristine—lymphatic system cancer	0.00165	0.00286	CcSEcCtD
Rifaximin—Diarrhoea—Teniposide—lymphatic system cancer	0.00165	0.00285	CcSEcCtD
Rifaximin—Mediastinal disorder—Vincristine—lymphatic system cancer	0.00164	0.00284	CcSEcCtD
Rifaximin—Myalgia—Bleomycin—lymphatic system cancer	0.00162	0.0028	CcSEcCtD
Rifaximin—Chest pain—Bleomycin—lymphatic system cancer	0.00162	0.0028	CcSEcCtD
Rifaximin—Back pain—Carmustine—lymphatic system cancer	0.0016	0.00278	CcSEcCtD
Rifaximin—Discomfort—Bleomycin—lymphatic system cancer	0.0016	0.00277	CcSEcCtD
Rifaximin—Mental disorder—Vincristine—lymphatic system cancer	0.00159	0.00276	CcSEcCtD
Rifaximin—Urine output increased—Methotrexate—lymphatic system cancer	0.00159	0.00275	CcSEcCtD
Rifaximin—Confusional state—Bleomycin—lymphatic system cancer	0.00156	0.00271	CcSEcCtD
Rifaximin—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00156	0.0027	CcSEcCtD
Rifaximin—Tremor—Carmustine—lymphatic system cancer	0.00155	0.00269	CcSEcCtD
Rifaximin—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00155	0.00269	CcSEcCtD
Rifaximin—Infection—Bleomycin—lymphatic system cancer	0.00154	0.00267	CcSEcCtD
Rifaximin—Anaemia—Carmustine—lymphatic system cancer	0.00153	0.00266	CcSEcCtD
Rifaximin—Back pain—Vincristine—lymphatic system cancer	0.00153	0.00265	CcSEcCtD
Rifaximin—Vomiting—Teniposide—lymphatic system cancer	0.00153	0.00265	CcSEcCtD
Rifaximin—Asthenia—Fludarabine—lymphatic system cancer	0.00152	0.00263	CcSEcCtD
Rifaximin—Rash—Teniposide—lymphatic system cancer	0.00152	0.00263	CcSEcCtD
Rifaximin—Dermatitis—Teniposide—lymphatic system cancer	0.00152	0.00263	CcSEcCtD
Rifaximin—Headache—Teniposide—lymphatic system cancer	0.00151	0.00261	CcSEcCtD
Rifaximin—Pruritus—Fludarabine—lymphatic system cancer	0.0015	0.00259	CcSEcCtD
Rifaximin—Back pain—Mitoxantrone—lymphatic system cancer	0.00149	0.00258	CcSEcCtD
Rifaximin—Anorexia—Bleomycin—lymphatic system cancer	0.00148	0.00256	CcSEcCtD
Rifaximin—Anaemia—Vincristine—lymphatic system cancer	0.00146	0.00253	CcSEcCtD
Rifaximin—Polyuria—Methotrexate—lymphatic system cancer	0.00145	0.00252	CcSEcCtD
Rifaximin—Hypotension—Bleomycin—lymphatic system cancer	0.00145	0.00251	CcSEcCtD
Rifaximin—Diarrhoea—Fludarabine—lymphatic system cancer	0.00145	0.00251	CcSEcCtD
Rifaximin—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.00143	0.00248	CcSEcCtD
Rifaximin—Nausea—Teniposide—lymphatic system cancer	0.00143	0.00248	CcSEcCtD
Rifaximin—Anaemia—Mitoxantrone—lymphatic system cancer	0.00143	0.00247	CcSEcCtD
Rifaximin—Vertigo—Vincristine—lymphatic system cancer	0.00142	0.00246	CcSEcCtD
Rifaximin—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00141	0.00245	CcSEcCtD
Rifaximin—Myalgia—Carmustine—lymphatic system cancer	0.00141	0.00245	CcSEcCtD
Rifaximin—Chest pain—Carmustine—lymphatic system cancer	0.00141	0.00245	CcSEcCtD
Rifaximin—Malaise—Mitoxantrone—lymphatic system cancer	0.00139	0.00241	CcSEcCtD
Rifaximin—Dyspnoea—Bleomycin—lymphatic system cancer	0.00138	0.00239	CcSEcCtD
Rifaximin—Confusional state—Carmustine—lymphatic system cancer	0.00137	0.00236	CcSEcCtD
Rifaximin—Dermatitis exfoliative—Methotrexate—lymphatic system cancer	0.00135	0.00234	CcSEcCtD
Rifaximin—Decreased appetite—Bleomycin—lymphatic system cancer	0.00135	0.00233	CcSEcCtD
Rifaximin—Myalgia—Vincristine—lymphatic system cancer	0.00135	0.00233	CcSEcCtD
Rifaximin—Cough—Mitoxantrone—lymphatic system cancer	0.00135	0.00233	CcSEcCtD
Rifaximin—Infection—Carmustine—lymphatic system cancer	0.00134	0.00233	CcSEcCtD
Rifaximin—Vomiting—Fludarabine—lymphatic system cancer	0.00134	0.00233	CcSEcCtD
Rifaximin—Rash—Fludarabine—lymphatic system cancer	0.00133	0.00231	CcSEcCtD
Rifaximin—Dermatitis—Fludarabine—lymphatic system cancer	0.00133	0.00231	CcSEcCtD
Rifaximin—Pain—Bleomycin—lymphatic system cancer	0.00133	0.0023	CcSEcCtD
Rifaximin—Headache—Fludarabine—lymphatic system cancer	0.00133	0.00229	CcSEcCtD
Rifaximin—Chest pain—Mitoxantrone—lymphatic system cancer	0.00131	0.00227	CcSEcCtD
Rifaximin—Myalgia—Mitoxantrone—lymphatic system cancer	0.00131	0.00227	CcSEcCtD
Rifaximin—Arthralgia—Mitoxantrone—lymphatic system cancer	0.00131	0.00227	CcSEcCtD
Rifaximin—Discomfort—Mitoxantrone—lymphatic system cancer	0.0013	0.00225	CcSEcCtD
Rifaximin—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00129	0.00224	CcSEcCtD
Rifaximin—Anorexia—Carmustine—lymphatic system cancer	0.00129	0.00223	CcSEcCtD
Rifaximin—Infection—Vincristine—lymphatic system cancer	0.00128	0.00222	CcSEcCtD
Rifaximin—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00128	0.00221	CcSEcCtD
Rifaximin—Confusional state—Mitoxantrone—lymphatic system cancer	0.00127	0.0022	CcSEcCtD
Rifaximin—Nervous system disorder—Vincristine—lymphatic system cancer	0.00127	0.00219	CcSEcCtD
Rifaximin—Hypotension—Carmustine—lymphatic system cancer	0.00127	0.00219	CcSEcCtD
Rifaximin—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.00126	0.00218	CcSEcCtD
Rifaximin—Nausea—Fludarabine—lymphatic system cancer	0.00126	0.00218	CcSEcCtD
Rifaximin—Infection—Mitoxantrone—lymphatic system cancer	0.00125	0.00217	CcSEcCtD
Rifaximin—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00125	0.00216	CcSEcCtD
Rifaximin—Shock—Mitoxantrone—lymphatic system cancer	0.00124	0.00214	CcSEcCtD
Rifaximin—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00123	0.00214	CcSEcCtD
Rifaximin—Urticaria—Bleomycin—lymphatic system cancer	0.00123	0.00213	CcSEcCtD
Rifaximin—Anorexia—Vincristine—lymphatic system cancer	0.00123	0.00213	CcSEcCtD
Rifaximin—Body temperature increased—Bleomycin—lymphatic system cancer	0.00123	0.00212	CcSEcCtD
Rifaximin—Insomnia—Carmustine—lymphatic system cancer	0.00122	0.00212	CcSEcCtD
Rifaximin—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00122	0.00212	CcSEcCtD
Rifaximin—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00122	0.00211	CcSEcCtD
Rifaximin—Hypotension—Vincristine—lymphatic system cancer	0.00121	0.00209	CcSEcCtD
Rifaximin—Dyspnoea—Carmustine—lymphatic system cancer	0.00121	0.00209	CcSEcCtD
Rifaximin—Anorexia—Mitoxantrone—lymphatic system cancer	0.0012	0.00208	CcSEcCtD
Rifaximin—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00118	0.00204	CcSEcCtD
Rifaximin—Decreased appetite—Carmustine—lymphatic system cancer	0.00118	0.00204	CcSEcCtD
Rifaximin—Hypotension—Mitoxantrone—lymphatic system cancer	0.00118	0.00204	CcSEcCtD
Rifaximin—Insomnia—Vincristine—lymphatic system cancer	0.00117	0.00202	CcSEcCtD
Rifaximin—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00117	0.00202	CcSEcCtD
Rifaximin—Pain—Carmustine—lymphatic system cancer	0.00116	0.002	CcSEcCtD
Rifaximin—Constipation—Carmustine—lymphatic system cancer	0.00116	0.002	CcSEcCtD
Rifaximin—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.00115	0.00199	CcSEcCtD
Rifaximin—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00114	0.00198	CcSEcCtD
Rifaximin—Decreased appetite—Vincristine—lymphatic system cancer	0.00112	0.00195	CcSEcCtD
Rifaximin—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00112	0.00194	CcSEcCtD
Rifaximin—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00112	0.00193	CcSEcCtD
Rifaximin—Feeling abnormal—Carmustine—lymphatic system cancer	0.00112	0.00193	CcSEcCtD
Rifaximin—Fatigue—Vincristine—lymphatic system cancer	0.00111	0.00193	CcSEcCtD
Rifaximin—Asthenia—Bleomycin—lymphatic system cancer	0.00111	0.00193	CcSEcCtD
Rifaximin—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00111	0.00192	CcSEcCtD
Rifaximin—Pain—Vincristine—lymphatic system cancer	0.00111	0.00191	CcSEcCtD
Rifaximin—Constipation—Vincristine—lymphatic system cancer	0.00111	0.00191	CcSEcCtD
Rifaximin—Pruritus—Bleomycin—lymphatic system cancer	0.0011	0.0019	CcSEcCtD
Rifaximin—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.00109	0.00189	CcSEcCtD
Rifaximin—Fatigue—Mitoxantrone—lymphatic system cancer	0.00109	0.00188	CcSEcCtD
Rifaximin—Pain—Mitoxantrone—lymphatic system cancer	0.00108	0.00186	CcSEcCtD
Rifaximin—Constipation—Mitoxantrone—lymphatic system cancer	0.00108	0.00186	CcSEcCtD
Rifaximin—Abdominal pain—Carmustine—lymphatic system cancer	0.00107	0.00185	CcSEcCtD
Rifaximin—Body temperature increased—Carmustine—lymphatic system cancer	0.00107	0.00185	CcSEcCtD
Rifaximin—Abdominal discomfort—Methotrexate—lymphatic system cancer	0.00106	0.00183	CcSEcCtD
Rifaximin—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00106	0.00183	CcSEcCtD
Rifaximin—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00104	0.0018	CcSEcCtD
Rifaximin—Neutropenia—Methotrexate—lymphatic system cancer	0.00103	0.00179	CcSEcCtD
Rifaximin—Dysuria—Methotrexate—lymphatic system cancer	0.00103	0.00179	CcSEcCtD
Rifaximin—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.00103	0.00178	CcSEcCtD
Rifaximin—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.00102	0.00177	CcSEcCtD
Rifaximin—Abdominal pain—Vincristine—lymphatic system cancer	0.00102	0.00177	CcSEcCtD
Rifaximin—Body temperature increased—Vincristine—lymphatic system cancer	0.00102	0.00177	CcSEcCtD
Rifaximin—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.00101	0.00174	CcSEcCtD
Rifaximin—Urticaria—Mitoxantrone—lymphatic system cancer	0.001	0.00173	CcSEcCtD
Rifaximin—Hypersensitivity—Carmustine—lymphatic system cancer	0.000997	0.00173	CcSEcCtD
Rifaximin—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000995	0.00172	CcSEcCtD
Rifaximin—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000995	0.00172	CcSEcCtD
Rifaximin—Pneumonia—Methotrexate—lymphatic system cancer	0.000989	0.00171	CcSEcCtD
Rifaximin—Vomiting—Bleomycin—lymphatic system cancer	0.000986	0.00171	CcSEcCtD
Rifaximin—Infestation—Methotrexate—lymphatic system cancer	0.000983	0.0017	CcSEcCtD
Rifaximin—Infestation NOS—Methotrexate—lymphatic system cancer	0.000983	0.0017	CcSEcCtD
Rifaximin—Depression—Methotrexate—lymphatic system cancer	0.00098	0.0017	CcSEcCtD
Rifaximin—Rash—Bleomycin—lymphatic system cancer	0.000978	0.00169	CcSEcCtD
Rifaximin—Dermatitis—Bleomycin—lymphatic system cancer	0.000977	0.00169	CcSEcCtD
Rifaximin—Asthenia—Carmustine—lymphatic system cancer	0.000971	0.00168	CcSEcCtD
Rifaximin—Hypersensitivity—Vincristine—lymphatic system cancer	0.000952	0.00165	CcSEcCtD
Rifaximin—Haematuria—Methotrexate—lymphatic system cancer	0.000937	0.00162	CcSEcCtD
Rifaximin—Epistaxis—Methotrexate—lymphatic system cancer	0.000927	0.00161	CcSEcCtD
Rifaximin—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000927	0.00161	CcSEcCtD
Rifaximin—Asthenia—Vincristine—lymphatic system cancer	0.000927	0.00161	CcSEcCtD
Rifaximin—Diarrhoea—Carmustine—lymphatic system cancer	0.000926	0.0016	CcSEcCtD
Rifaximin—Nausea—Bleomycin—lymphatic system cancer	0.000921	0.0016	CcSEcCtD
Rifaximin—Asthenia—Mitoxantrone—lymphatic system cancer	0.000903	0.00156	CcSEcCtD
Rifaximin—Dizziness—Carmustine—lymphatic system cancer	0.000895	0.00155	CcSEcCtD
Rifaximin—Haemoglobin—Methotrexate—lymphatic system cancer	0.000887	0.00154	CcSEcCtD
Rifaximin—Diarrhoea—Vincristine—lymphatic system cancer	0.000884	0.00153	CcSEcCtD
Rifaximin—Haemorrhage—Methotrexate—lymphatic system cancer	0.000883	0.00153	CcSEcCtD
Rifaximin—Pharyngitis—Methotrexate—lymphatic system cancer	0.000876	0.00152	CcSEcCtD
Rifaximin—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.000872	0.00151	CcSEcCtD
Rifaximin—Urethral disorder—Methotrexate—lymphatic system cancer	0.000865	0.0015	CcSEcCtD
Rifaximin—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000861	0.00149	CcSEcCtD
Rifaximin—Vomiting—Carmustine—lymphatic system cancer	0.000861	0.00149	CcSEcCtD
Rifaximin—Dizziness—Vincristine—lymphatic system cancer	0.000855	0.00148	CcSEcCtD
Rifaximin—Rash—Carmustine—lymphatic system cancer	0.000854	0.00148	CcSEcCtD
Rifaximin—Dermatitis—Carmustine—lymphatic system cancer	0.000853	0.00148	CcSEcCtD
Rifaximin—Headache—Carmustine—lymphatic system cancer	0.000848	0.00147	CcSEcCtD
Rifaximin—Tinnitus—Methotrexate—lymphatic system cancer	0.000823	0.00143	CcSEcCtD
Rifaximin—Vomiting—Vincristine—lymphatic system cancer	0.000822	0.00142	CcSEcCtD
Rifaximin—Rash—Vincristine—lymphatic system cancer	0.000815	0.00141	CcSEcCtD
Rifaximin—Dermatitis—Vincristine—lymphatic system cancer	0.000814	0.00141	CcSEcCtD
Rifaximin—Headache—Vincristine—lymphatic system cancer	0.00081	0.0014	CcSEcCtD
Rifaximin—Nausea—Carmustine—lymphatic system cancer	0.000804	0.00139	CcSEcCtD
Rifaximin—Angiopathy—Methotrexate—lymphatic system cancer	0.000801	0.00139	CcSEcCtD
Rifaximin—Vomiting—Mitoxantrone—lymphatic system cancer	0.0008	0.00139	CcSEcCtD
Rifaximin—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000795	0.00138	CcSEcCtD
Rifaximin—Rash—Mitoxantrone—lymphatic system cancer	0.000794	0.00137	CcSEcCtD
Rifaximin—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000793	0.00137	CcSEcCtD
Rifaximin—Headache—Mitoxantrone—lymphatic system cancer	0.000788	0.00137	CcSEcCtD
Rifaximin—Mental disorder—Methotrexate—lymphatic system cancer	0.000773	0.00134	CcSEcCtD
Rifaximin—Malnutrition—Methotrexate—lymphatic system cancer	0.000768	0.00133	CcSEcCtD
Rifaximin—Nausea—Vincristine—lymphatic system cancer	0.000768	0.00133	CcSEcCtD
Rifaximin—Nausea—Mitoxantrone—lymphatic system cancer	0.000748	0.00129	CcSEcCtD
Rifaximin—Back pain—Methotrexate—lymphatic system cancer	0.000743	0.00129	CcSEcCtD
Rifaximin—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000713	0.00123	CcSEcCtD
Rifaximin—Anaemia—Methotrexate—lymphatic system cancer	0.00071	0.00123	CcSEcCtD
Rifaximin—Malaise—Methotrexate—lymphatic system cancer	0.000693	0.0012	CcSEcCtD
Rifaximin—Vertigo—Methotrexate—lymphatic system cancer	0.00069	0.0012	CcSEcCtD
Rifaximin—Cough—Methotrexate—lymphatic system cancer	0.00067	0.00116	CcSEcCtD
Rifaximin—Chest pain—Methotrexate—lymphatic system cancer	0.000654	0.00113	CcSEcCtD
Rifaximin—Myalgia—Methotrexate—lymphatic system cancer	0.000654	0.00113	CcSEcCtD
Rifaximin—Arthralgia—Methotrexate—lymphatic system cancer	0.000654	0.00113	CcSEcCtD
Rifaximin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.00065	0.00112	CcSEcCtD
Rifaximin—Discomfort—Methotrexate—lymphatic system cancer	0.000646	0.00112	CcSEcCtD
Rifaximin—Confusional state—Methotrexate—lymphatic system cancer	0.000632	0.00109	CcSEcCtD
Rifaximin—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000627	0.00109	CcSEcCtD
Rifaximin—Infection—Methotrexate—lymphatic system cancer	0.000623	0.00108	CcSEcCtD
Rifaximin—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000615	0.00106	CcSEcCtD
Rifaximin—Skin disorder—Methotrexate—lymphatic system cancer	0.000609	0.00105	CcSEcCtD
Rifaximin—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000606	0.00105	CcSEcCtD
Rifaximin—Anorexia—Methotrexate—lymphatic system cancer	0.000598	0.00104	CcSEcCtD
Rifaximin—Hypotension—Methotrexate—lymphatic system cancer	0.000586	0.00101	CcSEcCtD
Rifaximin—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000571	0.000989	CcSEcCtD
Rifaximin—Insomnia—Methotrexate—lymphatic system cancer	0.000567	0.000982	CcSEcCtD
Rifaximin—Dyspnoea—Methotrexate—lymphatic system cancer	0.000559	0.000968	CcSEcCtD
Rifaximin—Decreased appetite—Methotrexate—lymphatic system cancer	0.000545	0.000944	CcSEcCtD
Rifaximin—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000541	0.000938	CcSEcCtD
Rifaximin—Fatigue—Methotrexate—lymphatic system cancer	0.000541	0.000936	CcSEcCtD
Rifaximin—Pain—Methotrexate—lymphatic system cancer	0.000536	0.000929	CcSEcCtD
Rifaximin—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000517	0.000895	CcSEcCtD
Rifaximin—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000513	0.000888	CcSEcCtD
Rifaximin—Urticaria—Methotrexate—lymphatic system cancer	0.000498	0.000863	CcSEcCtD
Rifaximin—Body temperature increased—Methotrexate—lymphatic system cancer	0.000496	0.000858	CcSEcCtD
Rifaximin—Abdominal pain—Methotrexate—lymphatic system cancer	0.000496	0.000858	CcSEcCtD
Rifaximin—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000462	0.0008	CcSEcCtD
Rifaximin—Asthenia—Methotrexate—lymphatic system cancer	0.00045	0.000779	CcSEcCtD
Rifaximin—Pruritus—Methotrexate—lymphatic system cancer	0.000444	0.000768	CcSEcCtD
Rifaximin—Diarrhoea—Methotrexate—lymphatic system cancer	0.000429	0.000743	CcSEcCtD
Rifaximin—Dizziness—Methotrexate—lymphatic system cancer	0.000415	0.000718	CcSEcCtD
Rifaximin—Vomiting—Methotrexate—lymphatic system cancer	0.000399	0.00069	CcSEcCtD
Rifaximin—Rash—Methotrexate—lymphatic system cancer	0.000395	0.000685	CcSEcCtD
Rifaximin—Dermatitis—Methotrexate—lymphatic system cancer	0.000395	0.000684	CcSEcCtD
Rifaximin—Headache—Methotrexate—lymphatic system cancer	0.000393	0.00068	CcSEcCtD
Rifaximin—Nausea—Methotrexate—lymphatic system cancer	0.000372	0.000645	CcSEcCtD
